The approved therapeutics are duvelisib, a PI3Kγ and PI3Kδ inhibitor for haematological malignancies [53], and imiquimod, a toll-like receptor 7 (TLR7) agonist for topical treatment of basal cell carcinoma [54]. The gene discussed is TLR7; the disease is basal cell carcinoma.